4.6 Article

Natural history and outcome of neuroendocrine carcinoma of the cervix

Journal

GYNECOLOGIC ONCOLOGY
Volume 141, Issue 2, Pages 247-254

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2016.02.008

Keywords

Cervical cancer; Neuroendocrine carcinoma; Squamous cell carcinoma; Cervical carcinoma; Cervix

Funding

  1. National Cancer Institute [NCI R01CA169121-01A1, NCI R01CA134964]

Ask authors/readers for more resources

Objective. Neuroendocrine carcinomas of the cervix (NECC) are rare and thought to be aggressive. We performed a population-based analysis to examine the natural history, treatment patterns and outcomes of women with NECC compared to squamous cell carcinoma (SCCC) and adenocarcinoma (AC) of the cervix. Methods. The National Cancer Database (NCDB) was utilized to identify women with NECC, SCCC, and AC treated from 1998 to 2011. Clinical, demographic, and treatment characteristics were compared between the groups. The association between tumor histology and survival was examined using Kaplan-Meier analyses and multivariable Cox proportional hazards regression models. Results. We identified 127,332 patients, including 1,896 (1.5%) with NECC and 101,240 ( 79.5%) with SCCC and 24,196 (19.0%) with AC. Patients with NECC were younger, more often white, commercially insured, and diagnosed with metastatic disease at presentation compared to women with SCCC. Patients with early-stage NECC were more likely to receive adjuvant chemotherapy and radiation after surgery (P < 0.05 for both). In multivariable models stratified by stage and adjusted for clinical and demographic characteristics, the risk of death was higher for patients with NECC compared to SCCC for all stages of disease: stages IB-IIA (HR = 2.96; 95% CI, 2.48-3.52), stages IIB-IVA (HR = 1.70; 95% CI, 1.45-1.99) and stage IVB (HR = 1.14; 95% CI, 0.91-1.43). Conclusion. NECC are aggressive tumors associated with an increased risk of death. Survival is inferior for NECC compared to squamous cell tumors for women with both early and advanced stage disease. (C) 2016 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available